

Michael Cabanero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1907310/publications.pdf>

Version: 2024-02-01

27
papers

1,283
citations

623734

14
h-index

610901

24
g-index

27
all docs

27
docs citations

27
times ranked

2640
citing authors

#	ARTICLE	IF	CITATIONS
1	A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. <i>Molecular Psychiatry</i> , 2008, 13, 197-207.	7.9	619
2	Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2017, 111, 23-29.	2.0	160
3	Prognostic value of RDW in cancers: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 16027-16035.	1.8	146
4	A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229). <i>Oncologist</i> , 2019, 24, 1439-1445.	3.7	40
5	SOX2 and PI3K Cooperate to Induce and Stabilize a Squamous-Committed Stem Cell Injury State during Lung Squamous Cell Carcinoma Pathogenesis. <i>PLoS Biology</i> , 2016, 14, e1002581.	5.6	35
6	Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 190-197.	10.7	34
7	<i>TP53</i> mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 346-352.	2.5	29
8	Association study of phosphodiesterase genes in the Sequenced Treatment Alternatives to Relieve Depression sample. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 235-238.	1.5	29
9	Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1490-1500.	1.1	26
10	BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer. <i>Lung Cancer</i> , 2020, 146, 78-85.	2.0	24
11	Management of Egfr-Mutated Non-Small-Cell Lung Cancer: Practical Implications from a Clinical and Pathology Perspective. <i>Current Oncology</i> , 2017, 24, 111-119.	2.2	19
12	Cancer proteome and metabolite changes linked to SHMT2. <i>PLoS ONE</i> , 2020, 15, e0237981.	2.5	18
13	Minimalist approaches to cancer tissue-of-origin classification by DNA methylation. <i>Modern Pathology</i> , 2020, 33, 1874-1888.	5.5	18
14	A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer. <i>Investigational New Drugs</i> , 2020, 38, 1077-1084.	2.6	15
15	Role for High-Affinity IgE Receptor in Prognosis of Lung Adenocarcinoma Patients. <i>Cancer Immunology Research</i> , 2017, 5, 821-829.	3.4	14
16	Computer-assisted image analysis of the tumor microenvironment on an oral tongue squamous cell carcinoma tissue microarray. <i>Clinical and Translational Radiation Oncology</i> , 2019, 17, 32-39.	1.7	14
17	ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases. <i>Lung Cancer</i> , 2020, 146, 350-354.	2.0	14
18	Tumor Platinum Concentrations and Pathological Responses Following Cisplatin-Containing Chemotherapy in Gastric Cancer Patients. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 801-807.	1.3	9

#	ARTICLE	IF	CITATIONS
19	Stability of Electrolyte Determinations on the Siemens Advia 1800 Analyzer. <i>Journal of Clinical Laboratory Analysis</i> , 2012, 26, 372-375.	2.1	5
20	Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib. <i>Clinical Lung Cancer</i> , 2020, 21, e488-e492.	2.6	5
21	Relationship between <i>JAK2V617F</i> mutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms. <i>Hematology</i> , 2017, 22, 354-360.	1.5	4
22	EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models. <i>Lung Cancer</i> , 2020, 145, 144-151.	2.0	4
23	Tumor platinum concentrations and pathological responses following preoperative cisplatin-containing chemotherapy in gastric or gastroesophageal junction cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 76-76.	1.6	1
24	Pathologically confirmed diffuse alveolar haemorrhage in lymphangioleiomyomatosis. <i>BMJ Case Reports</i> , 2021, 14, e238713.	0.5	1
25	CMET-30. COMPREHENSIVE METHYLOME ANALYSIS OF EGFR-MUTANT PRIMARY LUNG ADENOCARCINOMA AND MATCHED BRAIN METASTASIS. <i>Neuro-Oncology</i> , 2019, 21, vi58-vi58.	1.2	0
26	Taking action on actionable mutations: a French initiative on universality in precision cancer care. <i>Translational Cancer Research</i> , 2016, 5, S35-S39.	1.0	0
27	The effect of prior smoking history on the molecular profile of EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 8533-8533.	1.6	0